Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Arcutis reports promising topline phase IIb data on ARQ-151 for plaque psoriasis

July 23, 2019

Swedish MPA approves first-in-human trial of ILP-100

July 22, 2019

Affibody completes 12-week interim analysis of phase II psoriasis study of ABY-035

July 17, 2019

Galderma describes new mTOR inhibitors

July 15, 2019

Pfizer initiates phase II study of PF-06826647 for the treatment of plaque psoriasis

July 12, 2019

First patient dosed in phase II study of KD-025 in cutaneous systemic sclerosis

July 11, 2019

Cara initiates phase II trial of oral difelikefalin to treat pruritus in atopic dermatitis

July 10, 2019

Zhengzhou University describes Helicobacter pylori-neutrophil activating proteins

July 9, 2019

Promising topline results presented from phase III program of Epsolay in papulopustular rosacea

July 9, 2019

Almirall identifies acetyl-CoA carboxylase inhibitors

July 8, 2019

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...